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Summary
Objective: To compare the responsiveness of the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and a
questionnaire format of the Lequesne-Algofunctional Index in patients with OA of the lower extremities.
Methods: Longitudinal analysis of the instruments’ responsiveness [standardized response mean (SRM), effect size (ES)] in ambulatory
patients undergoing hip or knee arthroplasty.
Results: At six months 36, and at one year 40 out of 43 patients undergoing hip (N=30) or knee arthroplasty (N=13) could be examined. Both
responsiveness statistics revealed the same order of responsiveness. For both indices and for both locations, the pain sections were more
responsive than the function sections. However, the WOMAC scales and the WOMAC global index (hip at 12 months: SRM=2.4; knee at 12
months: SRM=2.0 ) were more responsive than the comparable Lequesne sections and Lequesne index (hip at 12 months: SRM=2.1; knee
at 12 months: SRM=1.5).
Conclusions: Although our results are based on a German version using a self-report format, the WOMAC scales appear to be more
responsive than the Lequesne index in patients with OA of the lower extremities. © 1999 OsteoArthritis Research Society International
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Comprehensive assessment of patients with osteoarthritis
(OA) of the lower extremities includes both measure-
ment of impairment and health-related quality of life.1–4
Health-related quality of life may be measured using con-
dition specific and generic health status questionnaires.5,6
Probably the two most widely used condition specific
instruments for the assessment of hip or knee OA are
the Lequesne-Algofunctional Index7–10 and the Western
Ontario and McMaster Universities Osteoarthritis Index
(WOMAC).2,4,11–16 Both instruments are recommended by
the OMERACT to measure the dimension of function in OA
trials.17 They cover not only physical functional disability
but also symptoms. However, whereas the WOMAC
addresses symptoms and functional disability in separate,
individually validated scales which may be aggregated into
a global index, the Lequesne OA-index directly aggregates
the items of a symptom and a function section which are
not graded separately. Also, the WOMAC is a patient
questionnaire whereas the Lequesne OA-index has been
developed as an interview format.2,8–10 In a recent analysis515of a self-administered questionnaire format we found the
Lequesne Index to have questionable metric properties.18
When deciding for a specific instrument to be used in a
clinical trial, or to be recommended by professional
societies to be included in core sets as exemplified by the
OMERACT guidelines, the most important dimension of an
instrument may be instrument responsiveness. To date
there is limited data on the responsiveness of the two
OA-indices and to the best of our knowledge they have not
been tested in a head to head comparison.
The objective of our study was to compare the respon-
siveness of the WOMAC and a questionnaire format of
the Lequesne OA-index in patients with OA of the lower
extremities. We used joint replacement surgery as a model
for a comparative analysis of the instruments’ responsive-
ness, an approach used before by others.19 We chose to
compare a self-report format because in clinical trials
it allows for mailing to patients and thus repeated
administration.Materials and methodsReceived 25 October 1998; accepted 15 April 1999.
Address for correspondence and reprint requests: G. Stucki, MD,
MS, Department of Physical Medicine and Rehabilitation, Ludwig-
Maximillans-University, Marchionistr. 15, Munich, Germany.PATIENTS AND DATA COLLECTION
Patients were recruited from the Departments of
Rheumatology and Orthopedic Medicine at the University
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orthopedics department in May 1995 to undergo joint
replacement surgery where asked by the study physician to
participate in the study. Patients were examined by the
study physician trained in standardized clinical data
assessment. Examination included assessment of the
combined clinical and radiological classification criteria for
OA20,21 and measurement of range-of-motion. After exami-
nation, patients were given the questionnaires. Patients
were invited for re-examination after 6 and 12 months.MEASURES
The WOMAC is a multi-dimensional measure of pain,
stiffness and physical functional disability.2,11–16 This index
has gained a growing acceptance in OA assessment since
its introduction in 1986. The pain scale includes five ques-
tions (S1–S5) asking about pain when ‘Walking on a flat
surface’ (S1), ‘Going up or down stairs’ (S2), ‘At night while
in bed’ (S3), ‘Sitting or lying’ (S4), ‘Standing upright’ (S5).
The stiffness scale includes two questions (St1, St2) asking
about stiffness ‘After first awakening in the morning’ (St1)
and ‘After sitting, lying or resting later in the day’ (St2). The
function scale (F1-F17) asks about the degree of difficulty
when ‘Descending stairs’, ‘Ascending stairs’, ‘Rising from
sitting’, ‘Standing’, ‘Bending to floor’, ‘Walking on flat’,
‘Getting in/out of car’, ‘Going shopping’, ‘Putting on socks/
stockings’, ‘Rising from bed’, ‘Taking off socks/stockings’,
‘Lying in bed’, ‘Getting in/out of bath’, ‘Sitting’, ‘Getting
on/off toilet’, ‘Heavy domestic duties’ and ‘Light domestic
duties’. Each of the in total 24 questions is graded either on
a Likert scale or a Visual Analogue Scale2 ranging from ‘no’
to ‘extreme’. In this study we used a numerical rating scale
ranging from 0 to 10 which is the preferred format in our
population.23,24 Similar to the Visual Analogue Scale it
provides interval-type data. To score each scale we calcu-
lated the mean of the item scores. The results thus equal
standardized WOMAC scores (standardization of WOMAC
scores is by division of the scale sum score by the number
of items).2 A global score was calculated as the unweighted
mean of the three scale scores. The scale scores as well as
the global score thus range from 0 to 10.
The Lequesne OA index directly aggregates symptoms
and function which are not graded separately. This index
has been used extensively in European OA studies since
1980. The index includes three sections with a total of 10
questions and takes a few minutes to complete. For the
purpose of this study we studied the three sections separ-
ately. The first section (1A-1E) asks about pain or dis-
comfort ‘At night’ (1A), ‘After getting up in the morning’ (1B),
‘When standing’ (1C) and ‘When walking’ (1D). The fifth
pain question (1E) addresses pain ‘When rising from sitting’
(knee index) and pain when ‘Sitting two hours’ (hip index).
Questions 1C and 1E are graded dichotomously: 0=no,
1=yes. Questions 1A, 1B and 1D have three categories
with 0=no; categories 1 and 2 are different for each
question (1A: 1=only with movement or in certain positions,
2=with no movement; 1B: 1=more than one but less than
15 minutes, 2=15 minutes or more; 1D: 1=only after
walking some distance, 2=initially and increasingly with
continued walking). The second section asks about the
maximum walking distance [graded from 0=unlimited to
6=less than 100 m (328 ft)]. If patients use one or two
walking aids the score is upgraded by one and two points,
respectively. The third section addresses physical function
disability with four categories graded from 0=withoutdifficulty to 2=unable to do. The knee index asks
about ‘Climbing one flight of stairs upward’, ‘Downward’,
‘Squatting’ and ‘Walking on uneven ground’. The hip index
asks about ‘putting on socks’, ‘Pick up an object on the
floor’, ‘Going up or down one flight of stairs’, ‘Getting out of
a car or a chair’. The Lequesne OA-index is scored as the
sum of all questions. The score range of each section is
from 0 to 8 resulting in a total score ranging from 0 to 24.
The Lequesne OA-index has been developed using an
interview format. Because we were interested in comparing
the performance of the two most widely used OA-specific
health status instruments using patient self-report we
adapted the Lequesne OA-index for questionnaire use.
Specifically, we added a question about the use of walking
aids.ANALYSES
A variety of statistics have been used to assess respon-
siveness and no single one is superior.24 Most commonly,
the responsiveness of health status instruments has been
compared using the standardized response mean (SRM)25
and the effect size (ES).26 The SRM is equal to the mean
change in score divided by the standard deviation (SD) of
individuals’ changes in scores. A higher SRM indicates
greater responsiveness. The ES is equal to the mean
change in score divides by the standard deviation of
individuals’ baseline score. ES thus relates change to the
initial variation of the individuals’ values.ResultsPATIENTS
Of the 53 patients initially asked to participate, 10
patients refused, leaving a sample of 43 patients with
baseline data. At 6 months 36 and at one year 40 out of 43
patients undergoing hip (N=30) or knee arthroplasty
(N=13) could be re-examined. At six months two patients
had died (for reasons unrelated to the arthroplasty), one
patient had emigrated and four patients refused to partici-
pate. At 12 months, all patients that were still alive and had
not emigrated could be examined. The mean age of the
population was 68.6 years (SD 13.8) and 60.5% were
female.RESPONSIVENESS STATISTICS
The responsiveness statistics are shown in Fig. 1 and
Tables I–III. Both responsiveness statistics resulted in the
same order of responsiveness, with respect to the sections
within the instrument and between the instruments.
For both indices and for both hip and knee, the pain
sections were more responsive than the function sections.
The stiffness scale, a component only of the WOMAC, was
less responsive than the pain and function scales for both
the hip and knee patients. Similarly, the Lequesne perform-
ance question, a component of only the Lequesne index,
was less responsive than the two other sections pain and
function.
The WOMAC’s pain and function scales were more
responsive than the comparable Lequesne sections. How-
ever, while the SRM for the WOMAC global index was more
sensitive than the Lequesne global index, the ES was
higher for the Lequesne global index.
Osteoarthritis and Cartilage Vol. 7 No. 6 517Fig. 1. Standardized Response Mean at 6 and 12 months. h, SRM 6 months, " SRM 12 months.Table I
Change in patient outcomes: baseline to 6 months
Pre-operative
Follow-up
at 6 months Change
t-test P-value ES SRMMean SD Mean SD Mean SD
WOMAC
Pain 5.36 1.82 0.69 1.01 −4.37 1.41 18.6 0.0001 2.40 3.10
Stiffness 5.52 2.6 1.68 1.99 −3.7 2.95 7.64 0.0001 1.42 1.25
Function 5.95 1.93 1.8 1.85 −4.02 1.83 13.38 0.0001 2.08 2.20
Global 5.61 1.81 1.38 1.39 −4.08 1.74 14.25 0.0001 2.25 2.34
LEQUESNE
Pain 6.83 1.94 2.30 2.14 −4.34 2.54 10.24 0.0001 2.24 1.70
Performance 4.73 2.30 2.33 1.77 −2.36 2.32 6.00 0.0001 1.03 1.02
Function 6.17 1.94 3.00 2.58 −3.37 2.26 8.93 0.0001 1.74 1.49
Global 5.91 1.53 2.38 1.97 −3.59 1.83 9.54 0.0001 2.35 1.96Table II
Change in patient outcomes: baseline to 12 months
Follow-up
at 12 months Change
t-test P-value ES SRMMean SD Mean SD
WOMAC
Pain 1.00 1.29 −4.25 1.55 17.31 0.0001 2.34 2.74
Stiffness 1.77 2.03 −3.68 3.15 7.5 0.0001 1.42 1.17
Function 1.77 1.95 −4.21 1.96 13.73 0.0001 2.18 2.15
Global 1.50 1.65 −4.10 1.98 13.2 0.0001 2.27 2.07
LEQUESNE
Pain 2.69 2.82 −4.32 2.78 9.54 0.0001 2.23 1.55
Performance 1.86 1.55 −2.75 2.18 7.46 0.0001 1.20 1.26
Function 2.78 2.67 −3.40 2.35 8.93 0.0001 1.76 1.45
Global 2.38 1.97 −3.59 1.83 12.13 0.0001 2.35 1.96Discussion
Patients with OA experience an important reduction of
their health. The burden of disease in our study as
measured with the WOMAC is comparable to a cohort of
hip OA patients reported by Laupacis (pain: 5.6 in our studycompared to 5.0 in Laupacis study; functional limitation: 6.0
compared to 5.7).27 Also, the burden was reduced impor-
tantly to similar levels after arthroplasty (pain: 0.5 in our
study compared to 0.7 in Laupacis study; stiffness: 1.6
compared to 1.0; function: 1.6 compared to 0.7).27 The
benefit of the intervention is reached within 6 months and
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first year after surgery.
The most important finding of our study is the superior
responsiveness of the WOMAC as compared to the
Lequesne index. This was true for the pain section and less
so for the global score. The reason for the inferior respon-
siveness of the WOMAC global index as compared to the
Lequesne index was the relatively low sensitivity of the
stiffness sub-scale. Since, in our calculation of the global
index, the stiffness sub-scale is being weighted equally to
the pain and function scale, the relatively low sensitivity
of the stiffness scale reduces the advantage of sensitivity of
the pain and function scales over the respective Lequesne
sections.
Based on these findings it may be preferable to use the
pain and/or function section or a global index only weighted
for the number of items (giving a weight of 17 to the
function scale, 5 to the pain scale and only 2 to the stiffness
scale) as primary endpoints for clinical studies. Differences
in responsiveness have important implications for clinical
research and practice. The ES allows calculation of sample
sizes for clinical trials.28,29 The larger the ES, the smaller
the sample size required for the study. For example, the
necessary sample size per treatment arm for detecting a
minimal clinically important difference of 1.0, assuming a
two sided type 1 error of 0.05 and a power of 0.8 would be
N=8 for ES=1.5, N=16 for ES=1 and N=64 for ES=0.5.
There are different possible explanations for the superior
responsiveness of the WOMAC. We used a German adap-
tation of the Lequesne index using a self-report format
instead of an interview. However, because we performed a
cultural adaptation following recently published guide-
lines,30,31 including translation and re-translation proce-
dures and committee review, which revealed no particular
problems,23,24 translation is an unlikely cause. While it is
unlikely that administration by an interview format which is
the original format of the Lequesne index would result in a
higher sensitivity, this could be tested. The grading of the
Lequesne symptom questions uses varying categories
such as ‘Presence of pain’, ‘Pain with movement’, ‘Duration
of pain’ and ‘Appearance of pain after a certain period
of time’, which may explain the lack of correlation
among the symptom items and consequently the inferior
responsiveness of the Lequesne index.18
The instrument responsiveness was comparable for hip
and knee patients, however a tendency to greater changes
in hip interventions was documented. As the sample size
for the whole study and more specifically for the hip andknee interventions was relatively small this data has to be
interpreted with caution.
Although our results are based on a German version
using a self-report format, the WOMAC scales appear to be
more responsive than the Lequesne index in patients with
OA of the lower extremities. We suggest that the WOMAC
is to be preferred as the primary endpoint in evaluative
studies of OA of the lower extremities.Acknowledgments
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Change in patient outcomes: 6 to 12 months
Change between
6 to 12 months
Mean SD t-test P-value ES SRM
WOMAC
Pain 0.11 2.62 0.25 0.81 0.05 0.05
Stiffness −0.06 1.89 −0.18 0.86 0.03 0.03
Function −0.07 1.48 −0.29 0.78 0.04 0.05
Global −0.03 1.25 −0.13 0.9 0.02 0.02
LEQUESNE
Pain 0.09 2.09 0.25 0.81 0.04 0.04
Performance −0.63 1.71 −2.07 0.05 0.36 0.37
Function −0.23 2.44 −0.56 0.58 0.09 0.09
Global −0.26 1.69 −0.90 0.38 0.13 0.15References
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